What is HC Wainwright’s Estimate for Valneva Q3 Earnings?

Valneva SE Sponsored ADR (NASDAQ:VALN) – Research analysts at HC Wainwright upped their Q3 2026 EPS estimates for shares of Valneva in a research report issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.18) for the quarter, up from their previous estimate of ($0.19). The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s FY2026 earnings at ($0.81) EPS, FY2027 earnings at $1.82 EPS, FY2028 earnings at $1.80 EPS and FY2029 earnings at $2.05 EPS.

Separately, Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Stock Performance

Shares of VALN opened at $6.49 on Monday. Valneva has a 1 year low of $5.43 and a 1 year high of $12.25. The stock’s fifty day moving average price is $10.22 and its two-hundred day moving average price is $9.67. The firm has a market cap of $558.85 million, a PE ratio of -4.11 and a beta of 1.79. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.38 and a quick ratio of 1.85.

Institutional Investors Weigh In On Valneva

Institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in Valneva during the 4th quarter worth approximately $44,000. Marex Group plc bought a new stake in Valneva in the second quarter valued at approximately $64,000. XTX Topco Ltd purchased a new stake in shares of Valneva during the fourth quarter valued at approximately $94,000. VSM Wealth Advisory LLC boosted its stake in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in shares of Valneva in the third quarter worth approximately $124,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Key Valneva News

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: Topline efficacy: The late?stage trial showed the vaccine reduced Lyme cases by more than 70%, indicating strong clinical activity and the potential to be the first new Lyme vaccine in decades. Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
• Positive Sentiment: Regulatory push: Pfizer and Valneva plan to pursue regulatory review despite the mixed statistical result, which keeps a path to approval and commercial rollout open. Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
• Neutral Sentiment: Mixed interpretation: Coverage notes the vaccine was “effective” but results aren’t conclusive — regulators will review the full dataset and statistical plan before deciding next steps. An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren’t conclusive
• Neutral Sentiment: Company stance: Pfizer says it’s confident in the candidate and points to low Lyme incidence during the trial as a reason the study missed its pre?specified statistical goal. Regulators may require additional briefing or analyses. Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
• Negative Sentiment: Missed primary endpoint: Multiple outlets emphasize the trial failed to meet its pre?specified statistical threshold (p?value), which elevates regulatory risk and could delay or complicate approval. Pfizer’s Lyme vaccine results set up tricky regulatory path
• Negative Sentiment: Market reaction: The mixed readout has prompted high trading volume and price weakness in VALN as investors weigh approval uncertainty, potential commercialization timing, and partner dynamics with Pfizer. Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.